|Day Low/High||0.57 / 0.62|
|52 Wk Low/High||0.49 / 3.59|
As a Miami resident, I've learned the value of hurricane preparation and the 'Jensen Rules'.
As a Florida resident, I've learned the value of preparation and the 'Jensen Rules'.
Key collaboration deals with deeper-pocketed concerns can improve the odds of investment success.
Here's how to lock in gains on risky small-cap biotechnology stocks.
I'm happy to once again be sitting in for Doug Kass today. It's been a remarkably boring week, with the major indices all trading in a narrow range. It feels like investors are unsure of stocks' next direction following first-quarter earnings season...
The market sold off in morning trading, despite a better-than-expected jobs report that showed new job creation of 295,000 for February and saw the unemployment rate falling again, to 5.5%. Wage growth is still not benefiting from stronger job growt...
The market is clawing its way back to even. Oil is holding gains, and this is translating into solid gains within the E&P space today so far. This is also helping Chicago Bridge & Iron (CBI) recover some of its losses from announcement of another de...
Scotts Miracle-No!, Synta's Sorrow and Google's Porn Problem highlight Gregg Greenberg's 5 Dumbest list this week.
TheStreet Sr. Columnist Adam Feuerstein says FDA reviews for cancer drugs from Aveo and Delcath are the next big thing in biotech.
These stocks may be speculative, but they sport solid sales-growth estimates -- and insiders are buying.
Some traders are shutting down for the year rather than trying to game the fiscal cliff.
Senior columnist Adam Feuerstein explains why cancer drug stocks are the next big thing in biotech.